The FDA approved Merck’s Keytruda drug to treat tumors with a certain genetic defect—the first time the agency has cleared a cancer drug for a use not tied to the site of a tumor. This represents a shift in the treatment of cancers, from a site driven (i.e. breast, lung, colon cancer) method to determining cancer treatment with a specific genetic mutation.
Course instructors, Beth and Rachel will share interesting articles about genetics, genomics and precision medicine that are in the news. Feel free to email them if you've come across an interesting article you'd like to share with other learners!